A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesized that udenafil, a newly developed phosphodiesterase type 5
inhibitor, would improve symptom, exercise capacity and hemodynamic status in patients with
mild pulmonary hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Dong-A Pharmaceutical Co., Ltd. Seoul National University Bundang Hospital